All Press releases are available in Swedish.
Cyxone can announce today that it has established a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.
- Operating revenue KSEK 0 (0)
- Income after financial items KSEK -1491 (-307)
- Earnings per share -0,10 (-0,04) SEK
- Cash and cash equivalents (2017-03-31) 31 275 (4 114) KSEK
- Equity ratio 98,2 (97,8) % as of 2017-03-31
Since 2016, Cyxone AB and Swiss pharmaceutical manufacturer Bachem AG have worked closely on the production of syntheses of Cyxone's development substance T20K, and on the production of substances for studies that started last year.
Cyxone can announce today that an independent research group at Monash University in Australia has confirmed the positive effects of the company's development substance T20K on multiple sclerosis (MS) symptoms in animal models as previously described.
Today, Cyxone announce that they will acquire the entire family of patents protecting the Company's main candidate T20K, from the Medical University of Vienna. The cost of € 100,930 includes VAT and corresponds to the costs of the patenting process.
Cyxone announce that T20K demonstrates no measurable toxic effect in mice after oral administration of up to 100 mg/kg in a single dose. Even at an oral dose of 250 mg/kg, half of the animals recovered well after treatment. Low toxicity of injected T20K has previously been reported by Cyxone.
The US Patent Office has announced its approval of Cyxone's patent on the cyclotide technology.
Cyxone has completed its first toxicity study of drug candidate T20K for the treatment of Multiple Sclerosis (MS) through the LPT Laboratory of Pharmacology and Toxicology GmbH in Germany.